Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Bamodu, Oluwaseun Adebayo ^a,b   Huang, Wen Chien ^c   Lee, Wei Hwa ^b   Wu, Alexander ^d,e   Wang, Liang Shun ^a,b   Hsiao, Michael ^f   Yeh, Chi Tai ^a,b   Chao, Tsu Yi ^a,b,g  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e ACADEMIA SINICA   (Taiwan)

^f GENOMICS RESEARCH CENTER   (Taiwan)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Anticancer target; Epigenetics; Histone demethylase; Hsa miR 448; KDM5B; Long non coding RNA; MALAT1; MicroRNA; Triple negative breast cancer

Indexed keywords

HISTONE DEMETHYLASE; HSA MICRORNA 448; LONG UNTRANSLATED RNA; LYSINE SPECIFIC DEMETHYLASE 5B PROTEIN; MALAT1 PROTEIN; MICRORNA; MYC PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; KDM5B PROTEIN, HUMAN; MALAT1 LONG NON-CODING RNA, HUMAN; MIRN448 MICRORNA, HUMAN; NUCLEAR PROTEIN; PROTEIN BINDING; REPRESSOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER STEM CELL; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WESTERN BLOTTING; BIOLOGICAL MODEL; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMISTRY; CLUSTER ANALYSIS; CONFORMATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR MODEL; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; RISK FACTOR; RNA INTERFERENCE; TUMOR CELL LINE;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICRORNAS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN BINDING; REPRESSOR PROTEINS; RISK FACTORS; RNA INTERFERENCE; RNA, LONG NONCODING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84959116049     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2108-5     Document Type: Article

References (58)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
3. Berrada N, Delaloge S, André F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. 2010;21 suppl 7:vii30-5.
4. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14(24):7988-99.
5. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013-23.
6. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010-8.
7. Gibb E, Brown C, Lam W. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38.
8. Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, Kondo S et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature. 2002;420(6915):563-73.
9. Huttenhofer A, Schattner P, Polacek N. Non-coding RNAs: hope or hype? Trends Genet. 2005;21(5):289-97.
10. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science. 2005;309(5740):1559-63.
11. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180-9.
12. Li L, Feng T, Lian Y, Zhang G, Garen A, Song X. Role of human noncoding RNAs in the control of tumorigenesis. Proc Natl Acad Sci. 2009;106(31):12956-61.
13. Wang Z, Tang F, Qi G, Yuan S, Zhang G, Tang B, et al. KDM5B is overexpressed in gastric cancer and is required for gastric cancer cell proliferation and metastasis. Am J Cancer Res. 2015;5(1):87-100.
14. Dai B, Hu Z, Huang H, Zhu G, Xiao Z, Wan W, et al. Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21. Biochem Biophys Res Commun. 2014;454(1):221-7.
15. T argetScan. http://www.targetscan.org/ Accessed 12 February 2014.
16. PicTar. http://pictar.mdc-berlin.de/ Accessed 12 February 2014.
17. miRANDA. http://www.microrna.org/microrna/home.do Accessed 12 February 2014.
18. The M-FOLD program. http://mfold.rna.albany.edu/?q=mfold Accessed 12 February 2014.
19. Bellucci M, Agostini F, Masin M, Tartaglia GG. Predicting protein associations with long noncoding RNAs. Nat Methods. 2011;8(6):444-5.
20. The Cancer Genome Atlas (TCGA). https://tcga-data.nci.nih.gov/tcga Accessed 12 February 2014.
21. The UCSC Cancer Browser. https://genome-cancer.ucsc.edu Accessed 12 February 2014.
22. Oncomine. https://www.oncomine.org/resource/ Accessed 12 February 2014.
23. The Gene Expression Omnibus (GEO). http://www.ncbi.nlm.nih.gov/geo Accessed 12 February 2014.
24. Muppirala U, Honavar V, Dobbs D. Predicting RNA-protein interactions using only sequence information. BMC Bioinformatics. 2011;12(1):489.
25. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835-40.
26. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31(13):3406-15.
27. GUI PyMOL software. http://pymol.org Accessed 18 May 2014.
28. CatRAPID software. http://big.crg.cat/gene_function_and_evolution/services/catrapid Accessed 18 May 2014.
29. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725-31.
30. Paolicchi E, Crea F, Farrar WL, Green JE, Danesi R. Histone lysine demethylases inbreast cancer. Crit Rev Oncol Hematol. 2013;86(2):97-103.
31. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat. 2012;131(3):777-89.
32. Rotili D, Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer. 2011;2(6):663-79.
33. Christensen J, Agger K, Cloos PA, Pasini D, Rose S, Sennels L, et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 2007;128(6):1063-76.
34. Scibetta AG, Santangelo S, Coleman J, Hall D, Chaplin T, Copier J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol. 2007;27(20):7220-35.
35. Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A. 2007;104(49):19226-31.
36. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25(6):801-12.
37. Barrett A, Madsen B, Copier J, Lu PJ, Cooper L, Scibetta AG, et al. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer. 2002;101(6):581-8.
38. Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, et al. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int J Cancer. 2012;131(3):E179-89.
39. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer. 2010;9(1):59.
40. McMullin R, Wittner B, Yang C, Denton-Schneider B, Hicks D, Singavarapu R, et al. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res. 2014;16(2):R25.
41. Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014;8(8):1429-40.
42. Carper MB, Denvir J, Boskovic G, Primerano DA, Claudio PP. RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells. Genes Cancer. 2014;5(11-12):420-35.
43. Chiu W-T, Lee H-T, Huang S, Aldape KD, Yao J, Steeg PS, et al. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by Stat3 inhibition. Cancer Res. 2011.
44. Liu XH, Lu KH, Wang KM, Sun M, Zhang EB, Yang JS, et al. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer. 2012;12(1):348.
45. Kanematsu S, Yoshizawa K, Uehara N, Miki H, Sasaki T, Kuro M, et al. Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice. Oncol Rep. 2011;26(3):603-8.
46. Kantara C, O'Connell MR, Luthra G, Gajjar A, Sarkar S, Ullrich RL, et al. Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab Invest. 2015;95(1):100-12.
47. Kleffel S, Schatton T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol. 2013;734:145-79.
48. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441(7091):349-53.
49. Dey BK, Stalker L, Schnerch A, Bhatia M, Taylor-Papidimitriou J, Wynder C. The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation. Mol Cell Biol. 2008;28(17):5312-27.
50. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485-92. 007, 7(1):8.
51. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol BioSyst. 2012;8(9):2289-94.
52. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol. 2009;20(12):1913-27.
53. Price C, Chen J. MicroRNAs in cancer biology and therapy: current status and perspectives. Genes Dis. 2014;1(1):53-63.
54. Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013;73(22):6554-62.
55. Braun JE, Huntzinger E, Fauser M, Izaurralde E. GW182 proteins directly recruit cytoplasmic deadenylase complexes to miRNA targets. Mol Cell. 2011;44(1):120-33.
56. Chen CY, Shyu AB. Mechanisms of deadenylation-dependent decay. Wiley Interdiscip Rev RNA. 2011;2(2):167-83.
57. Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature. 2009;457(7228):405-12.
58. Rothschild S. microRNA therapies in cancer. Mol Cell Ther. 2014;2(1):7.